These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22897391)

  • 1. Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
    Bennett HL; Stockley J; Fleming JT; Mandal R; O'Prey J; Ryan KM; Robson CN; Leung HY
    BJU Int; 2013 Apr; 111(4):672-82. PubMed ID: 22897391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.
    Müller SA; Holzapfel K; Seidl C; Treiber U; Krause BJ; Senekowitsch-Schmidtke R
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1434-42. PubMed ID: 19352653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
    Burich RA; Holland WS; Vinall RL; Tepper C; White RW; Mack PC
    BJU Int; 2008 Nov; 102(10):1458-66. PubMed ID: 18565171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the pro-survival side-effects of androgen-deprivation therapy in prostate cancer.
    Zecchini V; Neal DE
    BJU Int; 2013 Apr; 111(4):532-3. PubMed ID: 23551440
    [No Abstract]   [Full Text] [Related]  

  • 6. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
    De Petrocellis L; Ligresti A; Schiano Moriello A; Iappelli M; Verde R; Stott CG; Cristino L; Orlando P; Di Marzo V
    Br J Pharmacol; 2013 Jan; 168(1):79-102. PubMed ID: 22594963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.
    Ming L; Byrne NM; Camac SN; Mitchell CA; Ward C; Waugh DJ; McKeown SR; Worthington J
    Int J Cancer; 2013 Mar; 132(6):1323-32. PubMed ID: 22915157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.
    Kaini RR; Sillerud LO; Zhaorigetu S; Hu CA
    Prostate; 2012 Sep; 72(13):1412-22. PubMed ID: 22294520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation.
    Wang T; Alavian MR; Goel HL; Languino LR; Fitzgerald TJ
    Prostate; 2008 Dec; 68(16):1734-42. PubMed ID: 18729104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
    Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
    Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
    Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
    Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
    Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
    Carter SL; Centenera MM; Tilley WD; Selth LA; Butler LM
    BMC Cancer; 2016 Feb; 16():141. PubMed ID: 26907477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.